Tag Archive for: mcrpc
VIR-5500: A Promising T-Cell Engager for Advanced Prostate Cancer
/in Clinical Trial, Metastatic, Phase 1/by MaxPhase 3 Clinical Trial for Xaluritamig (AMG 509) in Advanced Prostate Cancer Set to Open for Recruitment Soon
/in Clinical Trial, Metastatic, Phase 3/by MaxBone-Modifying Agents Linked to Improved Survival in Advanced Prostate Cancer
/in Observational, Retrospective studies/by MaxSequencing Radium-223 and Lutetium-177 PSMA Therapy in mCRPC Management: Insights from the RaLu Trial
/in Clinical Trial, Metastatic, Phase 1/by MaxMatching-Adjusted Comparison of PARPi Therapies for mCRPC: Talazoparib + Enzalutamide Wins
/in Clinical Trial, Metastatic, Observational, Post-hoc, Retrospective studies/by MaxJanux Therapeutics Announces 100% Response in Phase 1a Results for JANX007 in mCRPC
/in Clinical Trial, Metastatic, Phase 1/by MaxProject Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
177Lu-PSMA-617 abiraterone abiraterone acetate ADC ADT AI ai in healthcare antibody-drug conjugate apalutamide ATM B7-H3 bispecific antibody bone metastases bone metastasis BRCA BRCA2 cancer immunotherapy CAR-T clinical trial crispr darolutamide docetaxel drug repurposing drug resistance enzalutamide HRR immunotherapy mcrpc metastatic hormone-sensitive prostate cancer mHSPC mRNA NEPC neuroendocrine prostate cancer oncolytic virus PARP1 PARP inhibitor Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data T-cell therapy theranostics
Latest Posts
- Newsletter 9/2026 March 1, 2026
- CT Muscle Measure Guides Treatment Benefit in New Prostate Cancer: STAMPEDE Findings February 25, 2026
- Igermetostat Plus Enzalutamide Delivers Promising rPFS in Post-Abiraterone mCRPC February 25, 2026
- UPLIFT Trial: Abemaciclib Safely Boosts PSMA for Better Radioligand Therapy in Advanced Prostate Cancer February 25, 2026